The U.S. Food and Drug Administration (FDA) today approved Celebrex (celecoxib) for a new use ? the relief of the signs and symptoms of Juvenile Rheumatoid Arthritis (JRA) in patients two years of age and older. Today’s approval follows the November 29 meeting of FDA’s Arthritis Advisory Committee, in which the committee voted 15 to 1 in favor of approval of this product.
Researchers are advancing against a rare, deadly lung disease (related to hormones) that no one had even heard of a decade ago. The disease targets only women, striking them down during their childbearing years. It can be triggered by pregnancy, progresses rapidly, and often results in death within 10 years.
A clinical trial to evaluate the safety of using a so-called gene vector to deliver a corrective gene to 12 patients with a common hereditary disorder that causes lung and liver disease is completed at the University of Florida. The gene therapy has caused no harmful effects in patients and hints at being effective.
The National Heart, Lung, and Blood Institute (NHLBI), one of the National Institutes of Health (NIH), and the Centers for Medicare & Medicaid Services (CMS) is launching the largest randomized clinical trial of the effectiveness and safety of long-term, home oxygen therapy for COPD (chronic obstructive pulmonary disease). The six-year, $28 million project will study patients with moderate disease.
Passive smoking does cause respiratory troubles in healthy adults, a new study confirms. The study is in the November issue of the American Journal of Respiratory and Critical Care Medicine.
Wal-Mart Stores, Inc., (NYSE: WMT) announced that starting today, it is rolling out its $4 generic prescription program in 11 additional states and adding 17 more prescriptions to the program. With the announcement, the expanded $4 generic prescription program will now be available in an additional 502 stores throughout Idaho, Kentucky, Maine, Massachusetts, Nebraska, Oklahoma, Rhode Island, South Carolina, Utah, Washington and West Virginia.
Wal-Mart Stores, Inc., (NYSE: WMT) announced that starting today, it is rolling out its $4 generic prescription program in 11 additional states and adding 17 more prescriptions to the program. With the announcement, the expanded $4 generic prescription program will now be available in an additional 502 stores throughout Idaho, Kentucky, Maine, Massachusetts, Nebraska, Oklahoma, Rhode Island, South Carolina, Utah, Washington and West Virginia.
There is no evidence antibiotics help the vast majority of patients with acute bronchitis, and doctors should stop routinely prescribing them, researchers reported on Wednesday.
In two studies presented during the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI), held in Philadelphia November 9-15, caregivers considered the ?seal of approval? from the FDA to be the most important factor when looking for an effective asthma treatment for their child. Caregivers and physicians also expressed in the study the need for a standardized assessment tool that could help diagnose and monitor asthma.
Children treated with PULMICORT RESPULES? (budesonide inhalation suspension) either once or twice daily experienced a significantly greater increase in the percentage of asthma-control days compared to those receiving placebo. These results are being presented at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI), held in Philadelphia on November 9-15. Asthma-control days were defined as days when children were free of symptoms and did not use rescue medications during the day and night. Control of asthma symptoms during the day and night and reduction of the need for rescue medication is an important goal of asthma therapy in keeping with current National Asthma Education and Prevention Program (NAEPP) guidelines.